Lysine-52 stabilizes the MYC oncoprotein through an SCFFbxw7-independent mechanism
- 14 August 2017
- journal article
- Published by Springer Nature in Oncogene
- Vol. 36 (49) , 6815-6822
Abstract
The oncogenic transcription factor c-MYC (MYC) is deregulated and often overexpressed in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease, suggesting that the development of therapeutic inhibitors targeting MYC would markedly impact patient outcome. MYC is highly regulated, with a protein and mRNA half-life of ~30 min. The most extensively studied pathway regulating MYC protein stability involves ubiquitylation and proteasomal degradation mediated by the E3-ligase, SCFFbxw7. Here we provide evidence for an SCFFbxw7-independent regulatory mechanism centred on the highly conserved lysine-52 (K52) within MYC Box I. This residue has been shown to be post-translationally modified by both ubiquitylation and SUMOylation, hinting at the interplay of post-translational modifications at this site and the importance of this residue. We demonstrate that mutation of K52 to arginine (R) renders the MYC protein more labile. Mechanistically, we show that the degradation pathway regulated by K52 is independent of the Cullin-RING ligase family of E3-ligases, which includes not only the canonical SCFFbxw7 but also other known MYC-targeting E3-ligases, such as SCFSkp2, SCFβTCRP, SCFFbxo28 and DCXTRUSS. Taken together, our data identify a novel regulatory pathway centred on K52 that may be exploited for the development of anti-MYC therapeutics.Keywords
This publication has 51 references indexed in Scilit:
- MYC Deregulation in Primary Human CancersGenes, 2017
- MYC: connecting selective transcriptional control to global RNA productionNature Reviews Cancer, 2015
- Taming of the beast: shaping Myc-dependent amplificationTrends in Cell Biology, 2015
- Therapeutic Strategies to Inhibit MYCCold Spring Harbor Perspectives in Medicine, 2014
- Transcriptional Amplification in Tumor Cells with Elevated c-MycCell, 2012
- MYC on the Path to CancerCell, 2012
- Myc proteins as therapeutic targetsOncogene, 2010
- Reflecting on 25 years with MYCNature Reviews Cancer, 2008
- The c-Myc target gene networkSeminars in Cancer Biology, 2006
- MYC oncogenes and human neoplastic diseaseOncogene, 1999